New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
07:55 EDTKYTHKythera price target raised to $55 from $50 at Leerink
Leeirnk raised its price target for Kythera shares to $55 after its survey indicated "significant demand" for the company's ATX-101, which aims to reduce submental fat. The firm keeps an Outperform rating on the stock.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
09:07 EDTKYTHKythera announces FDA advisory committee to review ATX-101 on March 9
Kythera announced the Dermatology and Ophthalmic Drugs Advisory Committee of the FDA is scheduled to review Kythera's New Drug Application, or NDA, for ATX-101 for improvement in the appearance of moderate to severe submental fullness in a half-day meeting on the morning of March 9. The date and details of the meeting are subject to confirmation by the FDA in a Federal Register notice. Kythera submitted the ATX-101 NDA to the FDA on May 12, 2014. The NDA will be subject to a standard review and has a Prescription Drug User Fee Act, or PDUFA, action date of May 13. The PDUFA date is the goal date for the FDA to complete its review of the NDA.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use